

POSTING OF PREAUTHORIZATION REQUIREMENTS

Navitus Preauthorization Approval/Denial Statistics 2020

Total Preauthorization Requests for 2020	Approved	Denied	Total
Off Exchange	365	256	621
On Exchange	3,570	3,472	7,033

Community Preauthorization Approval/Denial Statistics 2020

Total Number of Prior Authorizations Marketplace 2020	
Number of Providers requesting Prior Authorizations	7,449
Prior Authorization Request Reasons	
Neoplasms	8,423
Mental, Behavioral And Neurodevelopmental Disorders	1,257
Codes for Special Purposes	324
Diseases Of The Musculoskeletal System And Connective Tissue	13,025
Diseases Of The Digestive System	2,184
Factors Influencing Health Status And Contact With Health Services	3,695
Pregnancy, Childbirth And The Puerperium	524
External Causes Of Morbidity	44
Endocrine, Nutritional And Metabolic Diseases	2,235
Diseases Of The Respiratory System	1,852
Diseases Of The Eye And Adnexa	543
Certain Infections And Parasitic Diseases	601
Certain Conditions Originating In The Perinatal Period	88
Symptoms, Signs And Abnormal Clinical And Laboratory Findings, Not Elsewhere Classified	8,404
Diseases Of The Skin And Subcutaneous Tissue	1,257
Diseases Of The Ear And Mastoid Process	319
Congenital Malformations, Deformations And Chromosomal Abnormalities	287
Injury, Poisoning And Certain Other Consequences Of External Causes	2,383
Diseases Of The Genitourinary System	2,258
Diseases Of The Circulatory System	3,399
Diseases Of The Nervous System	3,462
Diseases Of The Blood And Blood-Forming Organs And Certain Disorders Involving The Immune Mechanism	788



	Den	ied Prior Authorizations	
Prior Authorization Partially Denied		1,141	
Approved		50,330	
Fully Denied		4,301	
Dismissed			1,580
		Denial Reasons	
Benefit Exclusion			581
Lack of Information		2,631	
Not Eligible			30
Not Medically Necessary		1,451	
Provider Out of Ne	Provider Out of Network		729
		Overturns	
Internal		95	
IRO			5
Drug/Class	Effective Date	Overview	
FERRIPROX	8/1/2021	Adding indication to PA	
FERRIPROX TYVASO INH SOLN	8/1/2021 8/1/2021	Adding indication to PA Adding indication to PA	
TYVASO INH		-	acute
TYVASO INH SOLN	8/1/2021	Adding indication to PA Updating PA form to clarify coverage for	acute
TYVASO INH SOLN NURTEC ODT	8/1/2021 8/1/2021	Adding indication to PA Updating PA form to clarify coverage for a treatment	acute
TYVASO INH SOLN NURTEC ODT CRINONE GEL	8/1/2021 8/1/2021 8/1/2021	Adding indication to PA Updating PA form to clarify coverage for a treatment Adding indication to PA	
TYVASO INH SOLN NURTEC ODT CRINONE GEL AYVAKIT TAB	8/1/2021 8/1/2021 8/1/2021 9/1/2021	Adding indication to PA Updating PA form to clarify coverage for a treatment Adding indication to PA Adding indication to PA	A
TYVASO INH SOLN NURTEC ODT CRINONE GEL AYVAKIT TAB TRIKAFTA TAB	8/1/2021 8/1/2021 8/1/2021 9/1/2021 9/1/2021	Adding indication to PA Updating PA form to clarify coverage for a treatment Adding indication to PA Adding indication to PA Adding expanded age indication to PA Adding limit of use in combination with vocl	A osporin
TYVASO INH SOLN NURTEC ODT CRINONE GEL AYVAKIT TAB TRIKAFTA TAB BENLYSTA INJ BENLYSTA AUTO	8/1/2021 8/1/2021 8/1/2021 9/1/2021 9/1/2021 9/1/2021	Adding indication to PA Updating PA form to clarify coverage for a treatment Adding indication to PA Adding indication to PA Adding expanded age indication to PA Adding limit of use in combination with vocl to PA Adding limit of use in combination with vocl	A osporin

07/26